Coherus BioSciences Management To Present At Two Investor Healthcare Conferences In November 

REDWOOD CITY, Calif., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that senior management will present at two upcoming investor healthcare conferences in November.
  • Management participation in a fireside chat is scheduled at Credit Suisse Scottsdale Healthcare Conference on Tuesday, November 8 th at 3:00 p.m. ET
  • A company presentation is scheduled at Jefferies 2016 London Healthcare Conference on Wednesday, November 16 th at 4:20 a.m. ET

The audio portion of the presentations will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.

About Coherus BioSciences, Inc.Coherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-0214 (etanercept biosimilar) and CHS-1420 (adalimumab biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology and multiple sclerosis. For additional information, please visit www.coherus.com.

CONTACT:Patrick O'BrienSenior Vice President, Investor RelationsCoherus BioSciences, Inc.pobrien@coherus.com+1 (650) 649-3527

Primary Logo

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Biotech Movers: Acceleron, Clovis, Coherus

Biotech Movers: Acceleron, Clovis, Coherus

Biotech Movers: Coherus, XBiotech, Flexion

Biotech Movers: Coherus, XBiotech, Flexion

AbbVie Stock Lower on Humira Patent Ruling

AbbVie Stock Lower on Humira Patent Ruling

Here's What Blackstone Bought and Sold in the Fourth Quarter

Here's What Blackstone Bought and Sold in the Fourth Quarter